Rani Therapeutics Holdings Inc. (RANI)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript
Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript
Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai
Rani Therapeutics is initiated at a Buy rating, driven by major pipeline advancements and strong partnership momentum. RANI secured a $1.085 billion collaboration with Chugai Pharmaceutical, leveraging RaniPill technology to target rare and immunological disorders with oral biologics. Positive preclinical data for RT-114 (oral GLP-1/GLP-2 agonist) and an oversubscribed $60.3 million private placement extend cash runway into 2028.
Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Talat Imran - CEO Svai Sanford - CFO Conference Call Participants Annabel Samimy - Stifel Eka Gigauri - Oppenheimer Julian Harrison - BTIG Mitchell Kapoor - H.C. Wainwright Chad Yahn - Maxim Group Xinwei An - Canaccord Genuity John Vandermosten - Zacks Operator Welcome to the Rani Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
Rani Therapeutics Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Farallon Capital Farallon Capital Management LLC | 78,000 | $105,300 | $51,737.4 | -$53,562.6 | -50.87% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 14,800 | $10,875 | $10,115.8 | -$759.2 | -6.98% |
 Li Peng China Universal Asset Management Co. Ltd. | 17,311 | $22,498.4 | $11,697.04 | -$10,801.36 | -48.01% |
 Christopher C. Powers Farther Finance Advisors, LLC | 13,800 | $18,630 | $9,622.74 | -$9,007.26 | -48.35% |
 Raymond Debbane Siren, L.L.C. | 2M | $2.7M | $1.34M | -$1.36M | -50.54% |
Rani Therapeutics Holdings Inc. (RANI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rani Therapeutics Holdings Inc. ever had a stock split?
Rani Therapeutics Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Talat Imran CEO | NASDAQ (NMS) Exchange | 753018100 CUSIP |
| US Country | 71 Employees | - Last Dividend | - Last Split | 30 Jul 2021 IPO Date |
Overview
Rani Therapeutics Holdings, Inc. represents a forefront player in the clinical stage biotherapeutics arena, focusing on the creation of orally administered biologics aimed at enhancing the treatment experience for patients, physicians, and healthcare systems within the United States. Established in 2012 and based in San Jose, California, the company pioneers in developing the RaniPill capsule. This innovative, drug-agnostic oral delivery platform stands out for its capability to administer a broad spectrum of drug substances orally – ranging from oligonucleotides and peptides to proteins and antibodies – traditionally delivered through injections. This breakthrough has the potential to significantly transform the administration of biologic treatments, making them more accessible and less invasive for patients.
Products and Services
- RT-102: RT-102 is positioned as a parathyroid hormone formulation currently undergoing a Phase I clinical trial. It is designed specifically for the treatment of osteoporosis, a condition characterized by weakened bones that are more susceptible to fracture. This product exemplifies Rani Therapeutics' effort to provide alternative therapeutic options that are orally administered, potentially offering a more patient-friendly approach compared to traditional injectables.
- RT-105: An innovative development in the pipeline, RT-105 is an anti-TNF-alpha antibody targeted for preclinical studies aimed at treating psoriatic arthritis. By focusing on this condition, Rani Therapeutics seeks to address the chronic pain, swelling, and stiffness associated with psoriatic arthritis through a novel oral formulation, which could revolutionize treatment adherence and effectiveness.
- RT-110: Another exciting offering in the realm of hormone replacement therapy, RT-110 is a parathyroid hormone intended for the treatment of hypoparathyroidism, a condition where the body produces an insufficient amount of parathyroid hormone. In keeping with the company’s innovative direction, this solution is being developed to deliver the hormone orally, marking a significant shift from the current injection-dependent treatments available for this condition.
- RT-111: Reflecting Rani Therapeutics’ commitment to expanding its biologic treatment offerings, RT-111 is under development as an ustekinumab biosimilar. Targeted for the treatment of various inflammatory conditions, RT-111 underscores the company's capacity to innovate within the biosimilar space, aiming to provide accessible, orally administrable options for conditions traditionally treated with injectable biologics.
